Answers are grounded in this paper and cite their sources.
The clinical study of CXCR1/2 inhibitors in combination with adoptively transferred NK cells is warranted.
No takes yet. Share an insight, caveat, or question.
Greene et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: